Showing results (1-10 of 152) with videos related to
Sort By:
Pageof 16
Biologics : Targets & Therapy|January 7, 2011
Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?Jürgen Frevert, Dirk DresslerJournal of Neural Transmission (Vienna, Austria : 1996)|May 5, 2026
Therapeutic botulinum toxin preparations: an updateHans Bigalke, Jürgen Frevert, Dirk DresslerToxicology|October 3, 2022
The immunology of botulinum toxin therapy: A brief summaryDirk Dressler, Hans Bigalke, Jürgen FrevertDrugs in R&D|August 12, 2010
Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®Jürgen FrevertToxicon : Official Journal of the International Society on Toxinology|March 19, 2009
Xeomin is free from complexing proteinsJürgen FrevertDrugs in R&D|January 7, 2015
Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A productsJürgen FrevertJournal of Neural Transmission (Vienna, Austria : 1996)|February 10, 2010
Comparing Botox and Xeomin for axillar hyperhidrosisDirk DresslerJournal of Neural Transmission (Vienna, Austria : 1996)|October 31, 2013
Tardive dystonic syndrome induced by the calcium-channel blocker amlodipineDirk DresslerMovement Disorders : Official Journal of the Movement Disorder Society|March 18, 2004
Clinical presentation and management of antibody-induced failure of botulinum toxin therapyDirk DresslerEuropean Neurology|July 26, 2002
Clinical features of antibody-induced complete secondary failure of botulinum toxin therapyDirk DresslerPageof 16